Craig Marshak
About Craig Marshak
Craig Marshak (age 66) has served as an independent director of Two Hands Corporation since January 3, 2025, with a finance and restructuring background and degrees from Duke University (A.B., summa cum laude, Phi Beta Kappa) and Harvard Law School (J.D.), and a scholarship to the London School of Economics . His tenure began following the December 2024 leadership transition; as of October 14, 2025, he is one of two independent directors on the Board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Clear Think Capital | Managing Director | Since March 2021 | Advisory/merchant banking; deal execution |
| SHR Ventures LLC (family office) | Senior Advisor | 2018–2021 | Strategic advisory; co-founded SPAC during period |
| Moringa Acquisition (NASDAQ-listed SPAC) | Vice Chairman and Co-Founder | Not disclosed (current per bio) | SPAC governance/transaction leadership |
| Israel Venture Partners | Principal | Since 2002 | Platform investing in Israeli tech/healthcare |
| Morgan Stanley (Merchant Banking) | Investment Banking | Not disclosed | Early career, merchant banking foundation |
| Wertheim Schroder / Schroders (London) | Corporate Finance & M&A | Not disclosed | Led complex restructurings (e.g., Manville) |
| Robertson Stephens (London) | Office Founder | Not disclosed | Established London office |
| Nomura Technology Merchant Banking Group (London) | Co-Head | 1998–2001 | Focused on Israeli/Silicon Valley high-growth firms |
External Roles
| Organization | Exchange | Role | Start Date | Committee Roles |
|---|---|---|---|---|
| Moringa Acquisition | NASDAQ | Vice Chairman & Co-Founder | Not disclosed | Not disclosed |
| Clear Think Capital | Private | Managing Director | March 2021 | Not disclosed |
| Israel Venture Partners | Private | Principal | 2002 | Not disclosed |
Note: The proxy also states “None of our directors are presently directors of other reporting issuers,” which appears to conflict with the biography’s current role at a NASDAQ-listed SPAC. Clarification from the company would be prudent .
Board Governance
- Independence: The Board determined two current directors are independent—Craig Marshak and Daniel Reshef .
- Committees: Audit Committee (members: Emil Assentato—Chair and identified “financial expert,” Craig Marshak, Daniel Reshef). Majority independent; Chair is the CEO, which weakens independence optics .
- Compensation & Nominating: No compensation or nominating committees; full Board oversees these functions due to company size/maturity .
- Board meetings: The Board held one (1) meeting during the year ended December 31, 2024 (before Marshak’s tenure); Audit Committee held one meeting in 2024 .
- Attendance: Not disclosed.
| Committee | Member | Chair | Independence Status |
|---|---|---|---|
| Audit | Yes | No | Independent director |
| Compensation | N/A | N/A | Committee not established |
| Nominating | N/A | N/A | Committee not established |
Fixed Compensation
- As of October 17, 2025, the company reports no director fees or equity awards for non-employee directors in 2022–2024; Marshak was appointed in 2025 and thus shows no compensation for prior years .
- The company does not currently have equity compensation plans in effect (as of year-end 2024) .
| Name | 2022 Total ($) | 2023 Total ($) | 2024 Total ($) |
|---|---|---|---|
| Craig Marshak | — | — | — |
Performance Compensation
- No director option-based or share-based awards outstanding; no value vested/earned for directors through 2024 .
- No disclosed performance metrics tied to director compensation (e.g., revenue, EBITDA, TSR) as of the 2025 proxy .
Other Directorships & Interlocks
| Company | Role | Interlocks with TWOH | Notes |
|---|---|---|---|
| Moringa Acquisition (NASDAQ SPAC) | Vice Chairman & Co-Founder | None disclosed | Bios state current service; proxy states none are directors of other reporting issuers—potential inconsistency |
Expertise & Qualifications
- Capital markets and restructuring expertise, including leadership on complex, multi-billion-dollar restructurings (Israel Chemicals privatization, Koor Industries, Manville Corporation) .
- Cross-border technology and healthcare investing (Israel, Silicon Valley) .
- Education: Duke University (A.B.), London School of Economics (Roger Alan Opel Scholarship), Harvard Law School (J.D.) .
Equity Ownership
- Marshak beneficially owns no shares of TWOH as of both February 21, 2025 and October 14, 2025 .
| As-of Date | Shares Beneficially Owned | % Outstanding |
|---|---|---|
| Feb 21, 2025 | — | — |
| Oct 14, 2025 | — | — |
Governance Assessment
-
Strengths:
- Independent director with deep capital markets and restructuring expertise .
- Audit Committee has a majority of independent members (Marshak and Reshef) .
-
Concerns:
- Audit Committee chaired by the CEO (not independent), which reduces perceived oversight independence in financial reporting—a governance weak point for investor confidence .
- No compensation or nominating committees; the full Board oversees these functions, atypical for best-practice governance even for small issuers .
- No disclosed director ownership or equity compensation for alignment; Marshak holds no shares, limiting “skin-in-the-game” optics .
- Proxy statement inconsistency: “no directors of other reporting issuers” vs. biography indicating current Vice Chairman role at a NASDAQ-listed SPAC, meriting clarification to avoid disclosure risk .
RED FLAGS
- Audit Committee chaired by non-independent CEO (independence majority but non-independent chair) .
- Absence of compensation and nominating committees, contrary to standard governance norms .
- Zero disclosed director share ownership and lack of equity compensation plan, suggesting weak ownership alignment .
- Disclosure inconsistency regarding external public company directorships (potential reporting issuer role) .
Related-party transactions and indebtedness: None disclosed for directors/officers in amounts >$120,000; no indebtedness to the company by directors/officers; no family relationships—reduces direct conflict risk .
Legal proceedings/penalties: Company is not aware of sanctions, bankruptcies, or legal proceedings involving nominees in the last 10 years; none noted for Marshak .
Notes on Role Initiation and Board Composition
- Appointment: Marshak was appointed to the Board on January 3, 2025 .
- Current Board (as of October 17, 2025): Emil Assentato (CEO), Matthew Stark (CFO), Craig Marshak (Director, independent), Daniel Reshef (Director, independent) .